United States · Markets & Finance · MarketWatch

Novo Nordisk Says FDA Review of Hemophilia Drug Is Hitting Delays

Published by MarketWatch · United States 11 h ago

Novo Nordisk received notice from the Food and Drug Administration that its review of denecimig for the treatment of hemophilia A is still ongoing. The FDA hasn't communicated a…

Read the full article on MarketWatch Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketwatch.com)

Also worth reading

NYT Business

Mark Ruffalo says Paramount’s $111 billion Warner Bros. deal ‘Will stifle creativity, weaken free speech, and cost people their jobs’

Business Insider

OpenAI safety leader David Robinson resigns as the team's upheaval mounts

CNBC

Novo Nordisk Says FDA Review of Hemophilia Drug Is Hitting Delays

Share

Also worth reading

White House Filing Claims President Has Authority to Bar News Outlets

Meta wants your next gadget to be Muse-infused

Power Play

Mark Ruffalo says Paramount’s $111 billion Warner Bros. deal ‘Will stifle creativity, weaken free speech, and cost people their jobs’

OpenAI safety leader David Robinson resigns as the team's upheaval mounts

Cerebras stock hits post-IPO low, tumbling 20% for the week on Nvidia pressure and lockup expiration